| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.70▼ | 1.72▼ | 1.73▼ | 1.78▼ | 1.48▲ |
| MA10 | 1.71▼ | 1.74▼ | 1.71▼ | 1.65▲ | 1.35▲ |
| MA20 | 1.72▼ | 1.71▼ | 1.77▼ | 1.53▲ | 1.40▲ |
| MA50 | 1.74▼ | 1.79▼ | 1.68▲ | 1.37▲ | 1.07▲ |
| MA100 | 1.71▼ | 1.66▲ | 1.54▲ | 1.40▲ | 1.15▲ |
| MA200 | 1.77▼ | 1.53▲ | 1.44▲ | 1.15▲ | 1.21▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | 0.001▲ | -0.013▼ | 0.023▲ | 0.007▲ |
| RSI | 28.202▼ | 43.177▼ | 46.668▼ | 57.969▲ | 66.175▲ |
| STOCH | 2.778▼ | 26.268 | 60.495 | 71.250 | 57.647 |
| WILL %R | -100.000▼ | -61.364 | -60.000 | -42.188 | -31.034 |
| CCI | -114.423▼ | -67.783 | -20.094 | 68.584 | 154.974▲ |
|
Friday, January 16, 2026 08:07 AM
Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment.
|
|
Thursday, January 15, 2026 05:55 AM
(Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positive preliminary 12-month data (~50% of patients evaluated to ...
|
|
Monday, January 12, 2026 01:32 AM
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 16/01/26 | 1.67 | 1.84 | 1.6312 | 1.69 | 8,158,688 |
| 15/01/26 | 1.86 | 1.86 | 1.58 | 1.62 | 13,969,167 |
| 14/01/26 | 1.94 | 1.96 | 1.85 | 1.88 | 7,055,800 |
| 13/01/26 | 1.80 | 1.95 | 1.66 | 1.91 | 15,436,970 |
| 12/01/26 | 1.555 | 1.79 | 1.544 | 1.78 | 10,033,573 |
| 09/01/26 | 1.50 | 1.55 | 1.475 | 1.50 | 2,877,774 |
| 08/01/26 | 1.55 | 1.57 | 1.49 | 1.49 | 3,740,028 |
| 07/01/26 | 1.54 | 1.65 | 1.54 | 1.59 | 4,613,927 |
| 06/01/26 | 1.45 | 1.58 | 1.45 | 1.54 | 5,988,725 |
| 05/01/26 | 1.40 | 1.46 | 1.32 | 1.45 | 4,930,683 |
|
|
||||
|
|
||||
|
|